Genitourinary Cancers

Treating primary tumors by administering targeted therapy with sunitinib (Sutent) prior to cytoreductive nephrectomy did not improve the progression-free rate at 28 weeks over a sequence of immediate CN followed by sunitinib in patients with synchronous metastatic renal cell carcinoma.

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was superior to sunitinib (Sutent) monotherapy as first-line treatment of advanced or metastatic renal cell carcinoma.

Ramucirumab (Cyramza) plus docetaxel improved progression-free survival over docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.

Patients with untreated advanced renal cell carcinoma lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent).

Lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) demonstrated promising antitumor activity in patients with metastatic clear cell renal cell carcinoma.

Atezolizumab with bevacizumab provided improved progression-free survival over sunitinib in patients with untreated metastatic renal cell carcinoma.

Mature results from the phase III KEYNOTE-045 study presented at the 2017 ESMO Congress demonstrated that overall survival with pembrolizumab (Keytruda) continued to improve compared to chemotherapy in patients with recurrent, advanced urothelial carcinoma.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC).

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the goals of the newly updated guidelines in renal cell carcinoma.

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the importance of multidisciplinary care in prostate cancer.

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the CABOSUN trial investigating cabozantinib (Cabometyx) and sunitinib (Sutent) in patients with renal cell carcinoma (RCC).

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.